Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 2/20 | 0.47 |
| ▸ | NPY4R | P50391 | 5/20 | 0.46 |
| ▸ | NPY1R | P25929 | 4/20 | 0.46 |
| ▸ | NPY2R | P49146 | 4/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CHRND | Q07001 | 5/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNG | P07510 | 1/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211861 | 0.88 | OPRD1 (0.49) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29527337 | 0.87 | OPRD1 (0.51) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL30365301 | 0.86 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29352830 | 0.86 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31211792 | 0.85 | MMP2 (0.48) | — | |
| SCHEMBL30609711 | 0.84 | CHRND (0.53) | CD40NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29365357 | 0.83 | OPRD1 (0.51) | OPRD1OPRM1OPRK1 | |
| SCHEMBL11512382 | 0.82 | IL23R (0.51) | CD40OPRD1OPRM1OPRK1 | |
| SCHEMBL31253360 | 0.82 | LNPEP (0.56) | OPRD1OPRM1OPRK1CHRNDCHRNA1 | |
| SCHEMBL29816050 | 0.82 | OPRD1 (0.49) | NPY4RNPY1RNPY2RNPY5ROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | EAGLE RESOLUTE INVESTMENT LLC | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | VIP, DNPEP, CD74 | CD40 76/4885NPY4R 2072/4885NPY1R 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.